Clinical-trials | Pharma Marketer

Clinical Trials Update: July 29, 2010 (HealthDay)

Thursday, July 29th, 2010

HealthDay – (HealthDay News) — Here are the latest clinical trials, courtesy of ClinicalConnection.com:

Posted in: headlines | 0 Comments »

Read the full story

Hospira plans big study for new Epogen biosimilar

Thursday, July 29th, 2010

In what’s described as an early-stage clinical trial, Hospira ( NYSE: HSP ) has unveiled plans to take its biosimilar of Amgen’s anemia drug Epogen directly into a head-to-head study

Posted in: Pharma News | 0 Comments »

Read the full story

Open-Source Pharmaceutical Babble

Thursday, July 29th, 2010

The topic of “open-source” drug discovery is an interesting (and potentially important) one. It just keeps coming up, but one of the problems with it is that it presents a terrible opportunity for vagueness. Too much of what I’ve read on the subject is hand-waving

Posted in: Clinical Trials | 0 Comments »

Read the full story

A little drug problem: perception

Tuesday, July 27th, 2010

For every million people who take a statin for high cholesterol, there are 50,000 fewer angioplasties, surgeries, heart-attacks, strokes, and CV deaths, studies have shown. In the past 15 years, drugs have transformed AIDS from a death sentence into a managed disease. A life saved or transformed because of the drug industry.

Posted in: DTC | 0 Comments »

Read the full story

Life Sciences Deals Go on Summer Break

Sunday, July 25th, 2010

The Burrill Report submits: By Marie Daghlian British consumer goods company Reckitt Benckiser ( RBGPF.PK ) agreed to buy SSL International, the maker of Durex condoms and Scholls footcare products, for $3.8 billion in cash, a 33 percent premium to SSL’s closing price the day before the announcement. It was the only major deal, albeit one on the fringes of life sciences, during a slow week. This is not the first time Reckitt has had its eyes on the complementary products in SSL’s portfolio, having courted the company back in 2003 when its shares were trading at a third of their present value.

Posted in: Clinical Trials, Pharma News, Regulatory | 0 Comments »

Read the full story

Vivus’s Obesity Drug Raises Familiar Questions

Sunday, July 25th, 2010

Derek Lowe submits: One big story from last week was the FDA advisory panel’s “No” decision on Qnexa, the drug-combo obesity therapy developed by Vivus ( VVUS ). This is the one that’s a combination of phentermine and topiramate, both of which have been around for a long time.

Posted in: Clinical Trials, Pharma News | 0 Comments »

Read the full story

Clinical Trials Update: July 23, 2010 (HealthDay)

Saturday, July 24th, 2010

HealthDay – (HealthDay News) — Here are the latest clinical trials, courtesy of ClinicalConnection.com:

Posted in: headlines | 0 Comments »

Read the full story

Lilly pushes deeper into men’s health

Friday, July 23rd, 2010

In an effort to become a leader in

Posted in: Pharma News | 0 Comments »

Read the full story

Vivus, Qnexa, Arena, Lorcaserin and the FDA

Friday, July 23rd, 2010

One big story from the last week was the FDA advisory panel’s “No” decision on Qnexa, the drug-combo obesity therapy developed by Vivus. This is the one that’s a combination of phentermine and topiramate , both of which have been around for a long time. And clinical trials showed that patients could indeed lose weight on the drug (with the required diet and exercise) – but also raised a lot of questions about safety

Posted in: Clinical Trials | 0 Comments »

Read the full story